Last reviewed · How we verify
Leucovorin (LV) — Competitive Intelligence Brief
phase 1
Live · refreshed every 30 min
Target snapshot
Leucovorin (LV) (leucovorin-lv) — Pfizer Inc.. Leucovorin enhances the effects of certain chemotherapy drugs by protecting normal cells from damage while not protecting cancer cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Leucovorin (LV) TARGET | leucovorin-lv | Pfizer Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Leucovorin (LV) CI watch — RSS
- Leucovorin (LV) CI watch — Atom
- Leucovorin (LV) CI watch — JSON
- Leucovorin (LV) alone — RSS
Cite this brief
Drug Landscape (2026). Leucovorin (LV) — Competitive Intelligence Brief. https://druglandscape.com/ci/leucovorin-lv. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab